Update on Herpes Zoster Vaccine: Licensure for Persons Aged 50 Through 59 Years

摘要

Herpes zoster vaccine (Zostavax, Merck & Co., Inc.) was licensed and recommended in 2006 for prevention of herpes zoster among adults aged 60 years and older.1 In March 2011, the Food and Drug Administration (FDA) approved the use of Zostavax in adults aged 50 through 59 years.2 In June 2011, the Advisory Committee on Immunization Practices (ACIP) declined to recommend the vaccine for adults aged 50 through 59 years and reaffirmed its current recommendation that herpes zoster vaccine be routinely recommended for adults aged 60 years and older.